HBIO

Image source: The Motley Fool. May 12, 2026 President and Chief Executive Officer — John Duke Chief Financial Officer — Mark Frost Senior Vice President, Ellipsis TA — Taylor Krafchik Need a quote from a Motley Fool analyst? Email [email protected] Operator: Good day, and welcome to the Q1 2026 Harvard Biosciences, Inc. Earnings Conference Call. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to Taylor Krafchik, Senior Vice President at Ellipsis TA. Please go ahead. Taylor Krafchik: Thank you, operator, and good morning, everyone. Thank you for joining the Harvard Bioscience First Quarter 2026 Earnings Conference Call. Leading the call today will be John Duke, President and Chief Executive Officer; and Mark Frost, Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the Investor Relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events or future financial performance and forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Biosciences management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Form 10-Q and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties and contingencies associated there within. During the call, management will also reference certain non-GAAP financial measures, which can be useful in evaluating the company's operations related to our financial condition and results. These non-GAAP measures are intended to supplement GAAP financial information and should not be considered as a substitute. Reconciliations of GAAP to non-GAAP measures are provided in today's earnings press release. I will now turn the call over to John. John, please go ahead. John Duke: Thanks, Taylor. Good morning, everyone, and thank yo...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Transitioning from a traditional tool provider to a leading supplier for the emerging translational science market, focusing on predictive human-relevant outcomes. New Product Innovation (NPI) portfolio, including Mesh MEA, BTX Electroporation, and SoHo Telemetry, grew to over 12% of total revenue compared to approximately 4% in the prior year. Sales to pharma and large biotech customers increased by more than 20% year-over-year, driven by the adoption of new approach methodologies and demand for deeper biological insights. Adjusted gross margin expanded by nearly 300 basis points to 59%, attributed to a shift toward higher-margin NPI revenue and operational cost actions implemented in late 2024. The 'Made in China' initiative was launched to address domestic sourcing incentives, starting with BTX products to mitigate regional headwinds and capture local market share. Project Viking manufacturing consolidation remains on track to move several product lines in Q2, targeting $3 million in savings for 2027 and $4 million annually thereafter. Full-year 2026 guidance reaffirmed with revenue growth of 2% to 4% and adjusted EBITDA growth of 6% to 10%, supported by a high-margin NPI pipeline. Anticipate double-digit revenue growth for the full year from the core NPI suite (Mesh MEA, BTX, and SoHo) as they become centerpieces of the translational strategy. U.S. academic sector results are expected to improve in Q2 and Q3 following the February NIH budget passage, as institutions must commit 'use it or lose it' funds by September 30. Management targets consistent gross margins greater than 60% and recurring revenue approaching 60% as the product mix shifts toward consumables and software. Q2 guidance assumes mid-single-digit year-over-year revenue growth and flat adjusted EBITDA due to the reinstatement of employee bonuses and increased sales activity investments. Inventory levels increased to $0.7 million in cash use to support improved lead times and prebuild requirements for the Project Viking facility transitions. Recorded $0.3 million in non-cash amortization interest expense and $0.2 million in non-cash exit fees related to the December 2025 debt facility. Incurred one-time administrative costs related to a 1-fo...

This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Harvard Bioscience Inc (NASDAQ:HBIO) reported Q1 revenue of $20.8 million, aligning with their expectations. Adjusted gross margin improved to 59%, a growth of nearly 300 basis points year-over-year. Sales of new product innovations like MESH MEA, BTX, and SOHO telemetry products drove growth, with expectations of double-digit revenue growth for the full year. Sales to pharma and large biotech customers grew more than 20% in the quarter compared to the previous year. The company is on track with Project Viking, a manufacturing consolidation initiative, expected to generate significant savings in the coming years. Revenue was slightly below the $21.8 million reported in Q1 2025, primarily due to lower sales from academic institutions in the Americas and distributors in APAC. Operating loss was $1.2 million, although significantly improved from a loss of $49.7 million last year due to goodwill impairment. Adjusted EBITDA was flat year-over-year and slightly below expectations due to higher investment in sales and marketing activities. Cash used in operations was $0.7 million, compared to cash generation of $3 million in the same quarter last year, due to higher inventory levels. Net debt increased by approximately $1.9 million from the prior year due to deferred finance costs related to a debt deal. Warning! GuruFocus has detected 9 Warning Signs with HBIO. Is HBIO fairly valued? Test your thesis with our free DCF calculator. Q: What portion of Harvard Bioscience's revenue is generated by the Mesh MEA, SOHO, and BTX product lines, and what is their expected growth? A: Mark Frost, CFO, stated that these product lines currently account for about 15% to 20% of the company's revenue and are expected to grow at double-digit rates throughout the year. Q: Are there any signs of increased activity in the academic sector following the approval of the federal budget? A: John Duke, CEO, confirmed that there is an increase in proposal activity and orders following the budget approval on February 3rd. This is expected to translate into revenue in Q2 as funds need to be committed by the end of the federal fiscal year. Q: How is the CRO spending trend, particularly in light of biotech financing? A: John Duke...

First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the first quarter ended March 31, 2026. “First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis,” said John Duke, President and Chief Executive Officer. “We are encouraged by the adoption rates of our NPI portfolio – specifically the MeshMEA™ organoid platform, and our BTX® Electroporation and SoHo™ Telemetry systems – which are deepening our reach into the biopharma sector. This shift toward a higher-margin product mix is expected to put us on a path toward consistent 60+% margin and higher recurring revenue. Additionally, our manufacturing consolidation is on track and is expected to yield significant efficiencies and cost savings. Looking ahead, we continue to focus on operational efficiency and believe we remain well positioned for our next phase of growth. We’re reaffirming our full year guidance, which anticipates high margin NPI sales growth driving bottom line growth in the second half of the year.” First Quarter 2026 Results For the first quarter of 2026, the Company reported revenues of $20.8 million compared to $21.8 million in the first quarter of 2025. Gross margin for the first quarter of 2026 was 59%, compared to 56% in the first quarter of 2025. Net loss for the first quarter of 2026 was $(3.4) million, compared to a net loss of $(50.3) million in the first quarter of 2025, which included goodwill impairment of $(48.0) million. Adjusted EBITDA for the first quarter of 2026 was $0.8 million compared to $0.8 million in the first quarter of the prior year. Cash (used) in and provided by operations was $(0.7) million during the three months ended March 31, 2026, compared to $3.0 million in the same period in 2025. The reduction in the cash balance is primarily due to one-time charges related to the process that resulted in the debt refinancing. This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures incl...

HOLLISTON, Mass. (AP) — HOLLISTON, Mass. (AP) — Harvard Bioscience Inc. (HBIO) on Tuesday reported a loss of $3.4 million in its first quarter. On a per-share basis, the Holliston, Massachusetts-based company said it had a loss of 77 cents. Losses, adjusted for amortization costs and pretax expenses, came to 33 cents per share. The medical instruments maker posted revenue of $20.8 million in the period. For the current quarter ending in June, Harvard Bioscience said it expects revenue in the range of $20.5 million to $22.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HBIO at https://www.zacks.com/ap/HBIO

HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website. About Harvard Bioscience Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com. Company Contact: Mark Frost Chief Financial Officer (508) 893-3120 [email protected]

This article first appeared on GuruFocus. Revenue: $23.7 million for Q4 2025, above the midpoint of guidance range. Gross Margin: 59.77% for Q4 2025, up 260 basis points from the previous year. Adjusted EBITDA: $3.8 million for Q4 2025, reflecting 27% year-over-year growth. Operating Income: $1.7 million for Q4 2025, up from flat last year. Adjusted Operating Income: $3.3 million for Q4 2025, up from $2.5 million last year. Full Year Revenue: $86.6 million, down from $94.1 million in 2024. Full Year Gross Margin: 57.77%, slightly down from 58.2% last year. Full Year Adjusted EBITDA: $8.1 million, up 12.5% from $7.2 million in 2024. Cash Flow from Operations: $6.7 million, up from $1.4 million in 2024. Net Debt: Reduced by $1.8 million to $31.4 million. Q1 2026 Revenue Guidance: $20 to $22 million. Full Year 2026 Revenue Growth Guidance: 2% to 4%. Full Year 2026 Adjusted EBITDA Growth Guidance: 6% to 10%. Warning! GuruFocus has detected 4 Warning Signs with HBIO. Is HBIO fairly valued? Test your thesis with our free DCF calculator. Release Date: March 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Harvard Bioscience Inc (NASDAQ:HBIO) completed a comprehensive refinancing, extending debt maturity to 2029 and reducing annual debt service, generating $3 million in annual cash savings. The company announced a strategic consolidation of its manufacturing footprint, expected to generate $3 million in savings in 2027 and $4 million thereafter. Revenue for the fourth quarter was $23.7 million, above the midpoint of guidance, with a gross margin of 60% at the high end of guidance. Adjusted EBITDA grew by 27% year over year to $3.8 million, driven by cost reductions and operational efficiency. Harvard Bioscience Inc (NASDAQ:HBIO) is evolving into a leading enabler of translational science, positioning itself in the $10 billion translational science market. Full year revenue for 2025 was down from $94.1 million to $86.6 million, primarily due to tariffs and delayed NIH funding. Gross margin for the full year decreased from 58.2% to 57.77%, impacted by lower revenue. The company faced a government shutdown of 43 days, impacting its ability to overachieve within the quarter. Revenue in the Americas and Europe saw declines due to lower academic and distribution sales. The company reported a GAAP loss per share...

Management characterized 2025 as a pivotal foundation-building year, focusing on improving financial flexibility and clarifying a long-term shift toward the $10 billion translational science market. The company is evolving from a traditional tools provider to an enabler of translational science, aiming to bridge the gap between animal models and human trials where 90% of drug candidates currently fail. Q4 performance was driven by a favorable mix shift toward higher-margin product lines and disciplined expense management, resulting in 27% year-over-year adjusted EBITDA growth. Strategic consolidation of manufacturing from Holliston to Minneapolis and European centers is expected to yield $3 million in savings in 2027 and $4 million annually thereafter. The company is intentionally prioritizing higher-margin consumables, service, and software, which now represent approximately 55% of total revenue, to improve visibility and durability. Management strengthened governance and leadership by appointing four new Board members and confirming Mark Frost as permanent CFO to support the transition to a platform-based technology provider. Full year 2026 guidance forecasts low single-digit revenue growth (2% to 4%) and high single-digit adjusted EBITDA growth (6% to 10%), driven by higher-margin new product innovation. Revenue is expected to ramp throughout the year on a year-over-year percentage basis, supported by stronger contributions from the NPI pipeline including SoHo telemetry and Mesh MEA. The 2026 outlook assumes the reinstatement of employee bonuses and merit-based compensation, which were suspended in 2025 due to macro headwinds. Management expects a positive impact from the February NIH funding approval to begin appearing in orders late in Q1, with primary revenue benefits realized in Q2. The company plans to continue deleveraging through a debt structure that requires no amortization in the first two years and offers potential conversion of debt to equity. A 43-day government shutdown during the fourth quarter impacted the company's ability to overachieve on revenue targets. Full year GAAP operating income was significantly impacted by a goodwill impairment charge taken earlier in 2025. The company successfully remediated material weaknesses and one significant deficiency in its financial reporting during the year. A comprehensive refinancing completed in...

HOLLISTON, Mass. (AP) — HOLLISTON, Mass. (AP) — Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $2.8 million in its fourth quarter. The Holliston, Massachusetts-based company said it had a loss of 6 cents per share. Earnings, adjusted for one-time gains and costs, came to less than 1 cent on a per-share basis. The medical instruments maker posted revenue of $23.7 million in the period. For the year, the company reported a loss of $56.7 million, or $1.28 per share. Revenue was reported as $86.6 million. For the current quarter ending in March, Harvard Bioscience said it expects revenue in the range of $20 million to $22 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HBIO at https://www.zacks.com/ap/HBIO

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results that reflect disciplined execution, an improved product mix, and the cost reductions implemented throughout the year,” said John Duke, President and Chief Executive Officer. “As we look ahead, we are evolving from a traditional life science tools provider into a leading enabler of translational science. By embracing the ongoing shift to New Approach Methodologies (NAMs) and focusing on new products for translational science, we’ll help our customers generate more predictive, human-relevant data earlier in the drug development process. We believe we are well-positioned for a new phase of growth and are confident in our outlook and our ability to drive sustainable shareholder value in 2026 and beyond.” “I’m pleased to have been appointed on a permanent basis and to continue working with the Harvard Bioscience team,” said Mark Frost, Chief Financial Officer. “We’ve made significant progress over the past year. I’m excited by the opportunity ahead, and I look forward to further engagement with our team, customers, and shareholders.” Fourth Quarter 2025 Results For the fourth quarter of fiscal 2025, the Company reported revenues of $23.7 million compared to $24.6 million in the fourth quarter of fiscal 2024. Gross margin for the three months ended December 31, 2025 was 59.7%, compared to 57.1% in 2024. The year-over-year increase was mostly due to the impact of cost containment actions and favorable product mix. Net (loss) income for the fourth quarter of 2025 was ($2.8) million compared to $18 thousand in the fourth quarter of 2024. Adjusted EBITDA for the fourth quarter of 2025 was $3.8 million compared to $3.0 million in the fourth quarter of the prior year. Cash (used in)...

Image source: The Motley Fool. Mar. 12, 2026 at 8 a.m. ET President and Chief Executive Officer — John Duke Chief Financial Officer — Mark Frost Need a quote from a Motley Fool analyst? Email [email protected] John Duke, President and Chief Executive Officer; and Mark Frost, Chief Financial Officer. In conjunction with today's call, we have provided a presentation that will be referenced during our remarks that is posted to the Investor Relations section of our website at investor.harvordbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management, expectations or future events or future financial performance are forward-looking statements and are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience management and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Form 10-K, which we expect will be filed within 24 hours of this call and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties and contingencies associated therewith. During the call, management will also reference certain non-GAAP financial measures, which can be useful in evaluating the company's operations related to our financial condition and results. These non-GAAP measures are intended to supplement GAAP financial information and should not be considered as a substitute. Reconciliations of GAAP to non-GAAP measures are provided in today's earnings press release. I will now turn 8: 03 AM the call over to John. John, please go ahead. John Duke: Thanks, Taylor, and good morning, everyone. Thank you for joining us for our fourth quarter and full year 2025 earnings call. On today's call, I'll review our recent actions, provide a brief overview of our fourth quarter financial results and then discuss our priorities and outlook for 2026. 2025 was a pivotal year of foundation building. Over the past 8 months, we improved our financial flexibility, took action to reorganize operations and clarified our long-term strategic direction. To recap, we too...